Ixel Cap. confirmed as 1st line treatment of fibromyalgia

The Korean Pain Society held the first International Congress on Spinal Pain (ICSP) at Chonnam National University Hwasum Hospital and Kimdaejung Convention Center, Gwangju to celebrate the 30th anniversary of the Society.

At this event, Professor Shin-Seok Lee of Rheumatology department, Chonnam National University presented about efficacy of Ixel Cap. (milnacipran), a serotonin-norepinephrine reuptake inhibitor, as the first-line treatment for fibromyalgia. He mentioned that “Ixel is not only helpful for alleviating pain but also effective in patients who have concomitant depression on top of their pain symptoms.” He emphasized that “adding Ixel 100mg to drug regimen of fibromyalgia patients who had an incomplete response to 300~450mg of pregabalin induces significant pain reduction.”

Ixel Cap. is a treatment for fibromyalgia and depression. Under Korean reimbursement rules, Ixel Cap. can be prescribed to fibromyalgia syndrome patients as 1st-line treatment regardless of tricyclic antidepressant use for one month. Also, there is no need of re-assessment after 13 weeks of use if the diagnosis of fibromyalgia syndrome is confirmed. Ixel. Cap. was developed by Pierre Fabre Medicacion (PFM) in France. It is manufactured and sold by Bukwang Pharmaceutical in Korea.

|    ​Korean    |